TRIAL DETAIL
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 04/01/2008 |
Age of Trial (yrs) 16.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CA191-002 |
|||
Sponsor: |
Bristol-Myers Squibb |
|||
Patient Contact: |
For site information outside the USA please email: Clinical.Trials@bms.com
First line of email MUST contain NCT# & Site#. |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
East Melbourne |
Victoria |
Australia |
|||
Heidelberg |
Victoria |
3084 |
Australia |
||
Parkville |
Victoria |
3050 |
Australia |
||
Footscray |
Victoria |
3011 |
Australia |